Empagliflozin

#41–Jake Kushner, M.D.: How to thrive with T1D and the valuable insights that can benefit anyone

Peter Attia MD

An SGLT2 inhibitor (referenced as 'epic of flows') that has shown a profound impact on cardiovascular outcomes, reducing complications by 40% in Type 2 Diabetes patients.